BACKGROUND: Recent treatment advances have greatly improved the prognosis of patients with multiple myeloma. However, some of these newer, more effective treatments are intensive and expensive and their use remains low, particularly among black patients. METHODS: In the current study, the authors reviewed the use patterns of stem cell transplantation and bortezomib using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database. RESULTS: After controlling for overall health and potential access barriers, black patients were found to be 37% (P<.0001) less likely to undergo stem cell transplantation, and 21% (P<.0001) less likely to be treated with bortezomib. Moreover, the authors found that the underuse of these treatments was associated with a 12% increase in the hazard ratio for death among black patients (P 5 0.0007). CONCLUSIONS: Eliminating health disparities, a current focus of US public policy, is highly complex, as illustrated by the results of the current study. In patients with multiple myeloma, treatment disparities are not completely explained by potential access barriers. Additional factors, such as structural barriers in the health care system and individual decision making among black and white patients, must be explored to fully explain the disparity. Cancer 2017;123:1590-6.
INTRODUCTION
Treatment advances over the past 2 decades have greatly improved the survival of patients with multiple myeloma (MM). 1 However, some of these newer, more effective treatments are often much more intensive and expensive than other treatment options and their use at the population level is low. For example, only approximately 13% of patients with MM undergo autologous stem cell transplantation (ASCT). 2 Use of ASCT also varies based on patient demographics. Older patients and those who are racial/ethnic minorities are less likely to undergo ASCT. 3, 4 Older patients are more likely to have comorbid conditions or other contraindications to the procedure and, until recently, the procedure was largely reserved for patients <78 years of age in part due to Medicare coverage guidelines. 5 These factors could account for the age-related disparity. The cause of the racial disparity is less clear. Researchers initially attributed it to access barriers such as low socioeconomic status (SES) and/or inadequate health insurance, 4 both of which have been linked to poorer survival in patients with MM. 6 However, our group recently reported that black patients treated at the study institution were 54% less likely to undergo ASCT after controlling for potential access barriers. 7 The objective of the current study was to confirm our previous findings regarding racial disparities in ASCT use among patients with MM in a nationally representative sample. We also reviewed the use patterns of bortezomib (BTZ) among white and black patients, a topic that to the best of our knowledge has not been reported to date. We chose BTZ as a comparator because it has largely become the standard of care in recent years and, unlike ASCT, BTZ is not exclusive to specialized centers; it can be administered at any facility that administers chemotherapy. We then analyzed how the use patterns of these 2 treatments impact outcome disparities in patients with MM.
MATERIALS AND METHODS

Data Source
The source of data for the current study was the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database. SEER collects demographics, tumor characteristics, and survival data from 18 population-based cancer registries throughout the United States, covering approximately 26% of the US population, including 23% of African American individuals. 8 In the SEER-Medicare linked database, the SEER registry data are linked to Medicare enrollment and claims data. Of all individuals >65 years of age in the SEER registry, approximately 93% have been matched to their corresponding Medicare data. 8 The SEER-Medicare database has been described in detail elsewhere. 9 At the time the current study was conducted, the SEER-Medicare linkage included all Medicare-eligible individuals appearing in the SEER data through 2011 and their Medicare claims through 2013.
The following Medicare claims files were used for this analysis: Medicare Provider Analysis and Review (MEDPAR), which includes all hospital short-stay, longstay, and skilled nursing facility bills (Medicare Part A); National Claims History (NCH), which includes all physician/supplier bills (Part B); Outpatient, which includes all bills from institutional outpatient providers (Part B); Home Health Agency (HHA), which includes all claims for home health services (Part B); and Durable Medical Equipment (DME), which includes all claims for durable medical equipment such as oxygen tanks (Part B).
Inclusion and Exclusion Criteria
In total, 46,328 patients diagnosed with MM between 2000 and 2011 were available in the SEER-Medicare database. Identification of MM was made using the World Health Organization (WHO) International Classification of Diseases for Oncology, Third Edition (ICD-O-3) histology codes 9731 to 9732 and 9734, which were all recoded to 34000 in the SEER database. 10 We excluded cases with duplicate or incomplete records including death certificate or autopsy cases, cases not enrolled in Medicare Part A and Part B at the time of diagnosis, and managed care enrollees (health maintenance organization). We also excluded all cases that did not have 1 claim within 1 year before diagnosis because this is another indicator of a possible incomplete record. We also excluded cases in which the reported race was not white or black or in which MM was diagnosed before age 65 years. Medicare eligibility before age 65 years is restricted to those individuals with severe illness or disability and thus these patients may not be generalizable. This left 20,916 patients for the analyses. Supporting Information Figure 1 details the screening flow chart.
The SCT use analysis was limited to patients who were aged <78 years at the time of diagnosis of MM because coverage for older patients was previously restricted as described above. The BTZ use analysis was limited to patients diagnosed after 2003 to coincide with its approval by the US Food and Drug Administration. The patients who were included in both the SCT and BTZ use analyses were included in the survival analysis.
Variables
Treatment use was determined using the Medicare claims data (NCH and Outpatient) with the International Classification of Diseases, Ninth Revision Clinical Modification (ICD-9-CM) diagnosis and procedure codes, which are used to identify claims for treatments or procedures.
11
The presence or absence of the corresponding procedure codes for ASCT ( 12 Therefore, we included the codes for the procedure to prevent this from confounding the analyses. BTZ use was determined by the presence or absence of the HCPCS code J9041.
Patients were coded as black or white and male or female based on SEER data. Age at the time of the diagnosis of MM and year of diagnosis were treated as continuous variables. We used SES, Medicaid enrollment, and geography to control for potential access barriers. Direct SES data at the patient level are not available through SEERMedicare. Instead, the database contains information from the 2000 Census reported at the tract level in which the patient lived at the time of diagnosis; the median household income (MHI), a continuous variable, was used to approximate SES. Patients enrolled in Medicaid at any time during the year of diagnosis were considered as enrolled. Geography was determined by the 2003 Rural-Urban Continuum Code from the Department of Agriculture's Economic Research Service for the county of home residence at the time of diagnosis.
Performance status (PS) is not directly available in the database. In its absence, Medicare claims were used to identify several claims-based indicators of PS, including the use of oxygen and related respiratory therapy supplies, wheelchairs and supplies, home health agency use, and skilled nursing facility use within 12 months before the diagnosis of MM. PS then was coded as normal (0 indicators) or poor (1 indicators) as previously described. 13 Comorbidities also were not directly available in the database. Diagnosis and procedure codes from the Medicare claims data (MEDPAPR, NCH, and Outpatient) for the 12 months before MM diagnosis were used to calculate a Charlson Comorbidity Index (CCI) score for each patient using established algorithms. 14, 15 Overall survival was defined as the number of months from the time of MM diagnosis to death from any cause. Patients still living were censored at the time of the data cutoff. Full details regarding variable coding can be found in Supporting Information Table 1 .
Statistical Analysis
Multivariate logistic regression models of ASCT and BTZ use were created in a stepwise fashion to determine how each set of variables influenced use. Initially, only race, sex, and year of diagnosis were included in the model (model 1). Overall health measures (age at diagnosis, PS, and CCI) then were added (model 2). Last, potential access barriers were added (MHI, Medicaid, and geography) (model 3). Cox regression models of survival then were created in a stepwise fashion to determine how each set of variables impacted overall survival. Initially, only race, sex, and year of diagnosis were included in the model (model 1). ASCT and BTZ use then were added (model 2). Last, overall health measures and potential access barriers were added (model 3).
Ethical Considerations
The current study was conducted as part of a research protocol approved by the Washington University Institutional Review Board. This specific analysis was exempt from Institutional Review Board review because the data were not individually identifiable and 
SCT Use
Approximately 54% of patients (11,269 patients) were eligible for the SCT use analysis. Overall SCT use was low;
only 7% of patients underwent the procedure. SCT use was found to be higher among white patients compared with black patients (8% vs 4%; chi-square 5 34.37 [P<.0001]). In the initial regression model, black patients were 49% less likely to use SCT than white patients (P<.0001). After controlling overall health, there was no change noted; black individuals were 49% less likely to use SCT (P<.0001). After also controlling for potential access barriers (MHI, Medicaid, and urban/rural status), black patients were found to be 37% less likely to undergo SCT (P<.0001). The model was significantly associated with SCT use (chi-square 5 508.02 (10) 
[P<.0001]).
Results from the regression models of SCT use are summarized in Table 2 .
BTZ Use
Approximately 77% of the entire patient cohort (16,037 patients) was eligible for the BTZ use analysis. Overall, 36% of patients used BTZ. Use was higher among white patients compared with black patients (36% vs 30%; chi-square 5 39.10 [P<.0001]). In the initial regression model, black patients were 24% less likely to use BTZ than white patients (P<.0001). After controlling overall health, the disparity increased; black patients were found to be 30% less likely to use BTZ (P<.0001). After also controlling for potential access barriers, black patients were found to be 21% less likely to use BTZ compared with white patients (P<.0001). The model was significantly associated with BTZ use (chi-square 5 1733.10 (10) [P<.0001]). Results from the regression models of BTZ use are summarized in Table 3 .
Survival
The survival analysis included 8625 patients who were eligible for both the SCT and BTZ use analyses. At the time of data cutoff, 69% of the patients (6013 patients) had died. Overall, the hazard ratio (HR) of black patients was 12% higher than that of white patients (P 5 .0007). After controlling for SCT and BTZ use, there was no significant difference in the HR noted between the 2 groups (P 5 .1124). When overall health and potential access barriers were added, the HR of black patients was 9% lower than that of white patients (P 5 .0068). The model was significantly associated with survival (chi-square 5 1026.66 (12) [P<.0001]). Results from the Cox regression survival models of are summarized in Table 4 .
DISCUSSION
In the current study, we found that disparities in treatment use for MM persist despite controlling for potential access barriers and overall health status. In our previous study of disparities in SCT use, black patients were found to be 51% less likely to undergo SCT compared with 37% in the current study. 7 The differences in results could be due to variations in methodology, such as patient selection (the previous study included patients of all ages, with a median age of 59 years at the time of diagnosis), or could represent differences in patients treated at a National Cancer Institute-designated Comprehensive Cancer Center versus the population in general.
The effects of overall health and potential access barriers on the disparities in SCT and BTZ use were very similar. After controlling for overall health, there was no change in underuse of SCT noted among black patients, but there was an increase in the underuse of BTZ. Although black patients in the current study were more likely to have indicators of poor PS and a higher CCI, they also on average were younger; therefore, differences in overall health did not explain the disparity in treatment use. Potential access barriers explained only a small amount of the underuse of SCT and BTZ. The similar results noted between SCT and BTZ indicate that 1) the disparity is not treatment specific and 2) the disparity is less likely due to referral bias. As noted above, although SCT is an intensive procedure that often requires inpatient hospitalization for weeks at a specialized facility that offers the procedure, BTZ can be administered on an outpatient basis in virtually any facility that administers chemotherapy.
Although structural barriers in the health care system (referral bias, cultural barriers, a lack of coordination of care, or conscious or unconscious bias among physicians) likely contribute to treatment disparities in MM, we hypothesize that differences in medical decision making between black and white patients also may be involved. Factors such as personal preferences or mistrust of the medical system (conscious or unconscious) may contribute to higher rates of black patients receiving inferior treatment. 17 Individual decision making often is overlooked in studies of cancer treatment disparities. However, we believe that this is a pivotal aspect because each patient at least in part determines his or her selected treatment course.
A strength of the current study is its generalizability because it is based on a nationally representative sample. However, there are several inherent limitations to studies using observational data. First, racial and ethnic minorities often are underrepresented in available data sets. The SEER database covers approximately 23% of African American individuals, but black patients only represented 16% of patients in the current study. In the SEER database, the average age at the time of diagnosis of MM is 65 years for black patients compared with 70 years for white patients. 18 Therefore, black patients in SEER are less likely to be eligible for Medicare, and thus black individuals are underrepresented in the SEER-Medicare database. Our previous study of SCT use included patients of all ages and insurance providers and the results were similar to those of the current study; therefore, we do not believe the underrepresentation impacted the findings herein. In addition, there is a small minority of patients with MM with asymptomatic or "smoldering" disease who do not require treatment; to the best of our knowledge, there currently is no validated claims-based method with which to identify them. However, the incidence of asymptomatic MM is similar between white and black patients and therefore should not confound comparisons of racial differences. 19 Another limitation of the current analysis is the lack of direct measures of SES and PS, and the use of surrogates for these measures. In addition, the database lacks any proxy variable for the success of stem cell mobilization. Therefore, it is possible that inferior stem cell mobilization among black patients could in part explain this disparity in ASCT use. However, this is not likely because black race has been associated with improved mobilization compared to white race. 20 Despite its limitations, the results of the current study highlight the complexity of health disparities.
In patients with MM, treatment disparities are not completely explained by variations in overall health and potential access barriers. We hypothesize that structural barriers in the health care system and differences in individual decision making between black and white patients likely contribute to the disparity.
FUNDING SUPPORT
No specific funding was disclosed.
CONFLICT OF INTEREST DISCLOSURES
Tanya M. Wildes' research was supported by grant 1K12CA167540 through the National Cancer Institute at the National Institutes of Health and grant UL1 TR000448 through the Clinical and Translational Science Award program of the National Center for Advancing Translational Sciences at the National Institutes of Health. The contents of the current study are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute, National Center for Advancing Translational Sciences, or National Institutes of Health.
